| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Magnesium silicate does not have a specific biological target but functions as a pharmaceutical excipient and food additive. It is used as an antacid to neutralize stomach acid and protect ulcer surfaces. The compound also functions as an anticaking agent, adsorbent, glidant, and processing aid in various formulations. In the pharmaceutical industry, it is used to absorb moisture, prevent caking, and improve the feel of a product. It is also used in cosmetics as talcum powder.
|
|---|---|
| ln Vitro |
Magnesium silicate is used as an antacid to neutralize stomach acid and protect ulcer surfaces. It functions as an adsorbent and anticaking agent in pharmaceutical and food formulations. The compound is employed for polyether adsorbent applications including adsorption, decoloring, and as an adsorbent in gas chromatography. It is used in vitamin analysis, antibiotic processing, and as an anticaking agent in food products. The compound is also used in cosmetics, plastics, insulation materials, and EVA shoe materials.
|
| ln Vivo |
In vivo, magnesium silicate is used as an antacid for the treatment of gastric and duodenal ulcers. It acts locally in the stomach to neutralize gastric acid and form a protective coating over ulcerated surfaces. The compound is not absorbed systemically and is excreted in the feces. It is also used as an anticaking agent in food products and as a processing aid in pharmaceutical formulations. The compound's safety and efficacy as an antacid have been established through clinical use.
|
| Enzyme Assay |
In vitro assays for magnesium silicate typically involve testing its acid-neutralizing capacity for antacid applications. The compound is incubated with simulated gastric fluid (0.1 N HCl) and the amount of acid neutralized is measured by titration. Adsorption assays involve incubating the compound with various substances (such as proteins, pigments, or toxins) in aqueous solution, followed by filtration and analysis of the supernatant. The compound's particle size, surface area, and purity are characterized using standard methods. The compound is typically dispersed in water or buffer for assay preparation.
|
| Cell Assay |
In vitro cellular assays for magnesium silicate are not typical, as the compound is used as an excipient or antacid rather than as a therapeutic agent targeting cellular pathways. The compound may be used in cell culture applications as an adsorbent or processing aid. Cytotoxicity assays may be performed to assess the compound's safety for pharmaceutical applications. For such assays, cells are incubated with varying concentrations of magnesium silicate (typically 0.1-1000 μg/mL) for 24-72 hours, and cell viability is assessed using MTT or other standard assays.
|
| Animal Protocol |
In vivo animal studies for magnesium silicate are typically conducted for toxicological evaluation rather than efficacy assessment. The compound may be administered orally to rodents at various doses for acute or repeated-dose toxicity studies. For antacid applications, the compound's acid-neutralizing effects can be evaluated in animal models of gastric ulcer. Standard endpoints include gastric pH, ulcer formation, and histopathological examination of the gastrointestinal tract. The compound is generally considered safe and is used as a food additive and pharmaceutical excipient.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of magnesium silicate indicate that it is not systemically absorbed. The compound acts locally in the gastrointestinal tract and is excreted in the feces. It has a molecular weight of approximately 140.69 g/mol (for Mg2O4Si). The compound appears as a white powder that is insoluble in water and ethanol. It is used as an anticaking agent, adsorbent, and glidant in oral pharmaceutical formulations and food products. The compound is stable under normal storage conditions.
|
| Toxicity/Toxicokinetics |
Magnesium silicate is generally recognized as safe (GRAS) for use as a food additive and pharmaceutical excipient. It is used as an anticaking agent in food products and as a glidant in pharmaceutical formulations. The compound is not absorbed systemically and has low toxicity. However, inhalation of the powder may cause respiratory irritation. Appropriate safety precautions should be taken when handling the compound in powdered form. It is not approved for therapeutic use as a drug but is used as an excipient and over-the-counter antacid.
|
| Additional Infomation |
Magnesium silicate (CAS 1343-88-0) is a compound of magnesium oxide and silicon dioxide, representing the magnesium salt of silicic acid. It appears as a white, odorless, tasteless powder that is insoluble in water or ethanol. The compound functions as an anticaking agent, adsorbent, glidant, and processing aid. It is used in pharmaceutical formulations as an excipient and antacid, in food products as an anticaking agent, and in various industrial applications including cosmetics and plastics. It is also known as activated magnesium silicate.
|
| Molecular Formula |
MGSIO3
|
|---|---|
| Molecular Weight |
100.389
|
| Exact Mass |
99.946
|
| CAS # |
1343-88-0
|
| PubChem CID |
72941442
|
| Appearance |
White to off-white solid powder
|
| Density |
3.21
|
| Melting Point |
1910°C
|
| Hydrogen Bond Acceptor Count |
3
|
| Heavy Atom Count |
5
|
| Complexity |
0
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Si]([O-])([O-])=O.[Mg+2]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :< 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.9612 mL | 49.8058 mL | 99.6115 mL | |
| 5 mM | 1.9922 mL | 9.9612 mL | 19.9223 mL | |
| 10 mM | 0.9961 mL | 4.9806 mL | 9.9612 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
